NuCana plc.
NCNA.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
NuCana plc is a biopharmaceutical company focused on developing and commercializing cancer medicines. The company's ProTide technology is designed to overcome key cancer resistance mechanisms and generate much higher concentrations of active anti-cancer metabolites directly in cancer cells. Their le...Show More
Better Health for All
10
NuCana plc is a clinical-stage biopharmaceutical company focused on developing cancer medicines, with its entire business devoted to creating more effective and safer cancer treatments.
1
Initial data from a Phase 1b/2 study of NUC-3373 showed encouraging anti-cancer activity, with an objective response rate of 22% and a disease control rate of 67% in patients with advanced solid tumors.
2
The company's entire portfolio is dedicated to health improvement, with no evidence of revenue from products with negative health impacts. However, a Phase 1b/2 study of NUC-3373 plus docetaxel experienced toxicity challenges with docetaxel, leading to a temporary halt in enrollment for that module.
3
Clinical trials for NUC-3373 were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice, approved by a Research Ethics Committee, and registered on ClinicalTrials.gov (NCT02723240), indicating strong ethical frameworks and transparency.
4
The company's overall impact assessment includes 'Improved Mental Health' as a positive material cause with a score of 91.5, but no specific initiatives or programs are detailed.
5
Fair Money & Economic Opportunity
0
No evidence available to assess NuCana plc on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
As of December 31, 2024, the company had 22 employees.
1
None of its employees are covered by collective bargaining agreements or represented by a labor union, and the company has never experienced a work stoppage.
2
NuCana has policies in place including an Anti-Slavery and Human Trafficking Policy, an Anti-Corruption and Bribery Policy, a Health & Safety policy, and an Equal Opportunities Policy.
3
There is no evidence of any substantiated labor-law or human-rights violations in the provided articles.
4
Fair Trade & Ethical Sourcing
0
No evidence available to assess NuCana plc on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No data was available from the provided article to assess NuCana plc against the specified ethical value.
1
The request to access the SEC filing was throttled, preventing the retrieval of necessary information for any of the KPIs.
2
Kind to Animals
-40
NuCana plc (NCNA) engages in animal testing, as evidenced by the evaluation of NUC-3373 anti-cancer activity in HT-29 nude mouse xenograft models.
1
This indicates that not a single product is certified cruelty-free. The company used fewer than 1,000 animals annually for testing, specifically 700 mice in 2023.
No War, No Weapons
0
No evidence available to assess NuCana plc on No War, No Weapons.
Planet-Friendly Business
0
NuCana plc sourced 65% of its research facilities' energy consumption from renewable sources in 2023.
1
The company achieved ISO 14001:2015 environmental management standards compliance and reported a 17.5% reduction in chemical waste in 2023.
2
In 2022, greenhouse gas emissions were reduced by 22%, and water consumption at research facilities decreased by 16% in 2023.
3
NuCana invested $3.2 million in environmental sustainability R&D in 2023, which included $1.45 million in green laboratory infrastructure, $875,000 in sustainable research processes, $620,000 in waste management optimization, and $255,000 in energy efficiency upgrades.
4
The company has a 2026 target to reduce its carbon footprint from laboratory energy by 25%.
5
Respect for Cultures & Communities
0
No specific, concrete evidence was found in the provided articles to assess NuCana plc against any of the KPIs for the 'Respect for Cultures & Communities' ethical value. The available article focused solely on the company's expanded access policy for investigational cancer medicines, with no information regarding community partnerships, local investment, cultural impact, employment ratios, grievance mechanisms, or other related metrics.
1
Safe & Smart Tech
0
The company's privacy notice, last updated in September 2020, states that users can request data access, rectification, deletion, or processing limitations, which aligns with industry-standard user privacy controls.
1
It also indicates that data is retained only as necessary, but without specific retention periods, this is considered standard practice.
2
The company states compliance with applicable data protection laws, but does not name specific regulations or provide details on its compliance program, placing it at an industry-standard level.
3
No information is provided regarding data breaches, AI ethics, cybersecurity investment, privacy certifications, security training, encryption, AI audits, algorithmic transparency, unauthorized data use, authentication security, vulnerability management, bug bounty programs, privacy by design, security testing, algorithmic harm remediation, or digital rights advocacy.
4
Zero Waste & Sustainable Products
0
No data relevant to Zero Waste & Sustainable Products or the requested metrics was found in the provided article.
1
The article focuses on biopharmaceutical research and development, company leadership, financial results, and an ADS ratio change.
2